These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 35904217)

  • 1. Testosterone in men with hypogonadism and transgender males: a systematic review comparing three different preparations.
    Madsen MC; Heijer MD; Pees C; Biermasz NR; Bakker LEH
    Endocr Connect; 2022 Aug; 11(8):. PubMed ID: 35904217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The HEAT-Registry (HEmatopoietic Affection by Testosterone): comparison of a transdermal gel vs long-acting intramuscular testosterone undecanoate in hypogonadal men.
    Zitzmann M; Cremers JF; Krallmann C; Kliesch S
    Aging Male; 2022 Dec; 25(1):134-144. PubMed ID: 35467476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testosterone therapy--what, when and to whom?
    Jockenhövel F
    Aging Male; 2004 Dec; 7(4):319-24. PubMed ID: 15799128
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 8-Year Treatment of Long-Acting Testosterone Undecanoate on Metabolic Parameters, Urinary Symptoms, Bone Mineral Density, and Sexual Function in Men With Late-Onset Hypogonadism.
    Permpongkosol S; Khupulsup K; Leelaphiwat S; Pavavattananusorn S; Thongpradit S; Petchthong T
    J Sex Med; 2016 Aug; 13(8):1199-211. PubMed ID: 27436076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testosterone deficiency and replacement.
    Howell S; Shalet S
    Horm Res; 2001; 56 Suppl 1():86-92. PubMed ID: 11786693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Testosterone replacement therapy in male hypogonadism.
    Byrne M; Nieschlag E
    J Endocrinol Invest; 2003 May; 26(5):481-9. PubMed ID: 12906378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EMAS position statement: Testosterone replacement therapy in older men.
    Kanakis GA; Pofi R; Goulis DG; Isidori AM; Armeni E; Erel CT; Fistonić I; Hillard T; Hirschberg AL; Meczekalski B; Mendoza N; Mueck AO; Simoncini T; Stute P; van Dijken D; Rees M; Lambrinoudaki I
    Maturitas; 2023 Dec; 178():107854. PubMed ID: 37845136
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficacy, safety, and outcomes of testosterone use among transgender men patients: A review of the literature.
    Mwamba RN; Ekwonu A; Guimaraes PVB; Raheem OA
    Neurourol Urodyn; 2023 Jun; 42(5):921-930. PubMed ID: 36403286
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Hematocrit Change in Testosterone-deficient Men Treated With Intranasal Testosterone Gel vs Intramuscular Testosterone Cypionate: A Randomized Clinical Trial.
    Rivero MJ; Ory J; Diaz P; Thirumavalavan N; Han S; Reis IM; Ramasamy R
    J Urol; 2023 Jul; 210(1):162-170. PubMed ID: 37126399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bone mineral density outcomes following long-term treatment with subcutaneous testosterone pellet implants in male hypogonadism.
    Zacharin MR; Pua J; Kanumakala S
    Clin Endocrinol (Oxf); 2003 Jun; 58(6):691-5. PubMed ID: 12780744
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Injection of testosterone may be safer and more effective than transdermal administration for combating loss of muscle and bone in older men.
    Borst SE; Yarrow JF
    Am J Physiol Endocrinol Metab; 2015 Jun; 308(12):E1035-42. PubMed ID: 25898953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Male hypogonadism : an update on diagnosis and treatment.
    Darby E; Anawalt BD
    Treat Endocrinol; 2005; 4(5):293-309. PubMed ID: 16185098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline.
    Bhasin S; Brito JP; Cunningham GR; Hayes FJ; Hodis HN; Matsumoto AM; Snyder PJ; Swerdloff RS; Wu FC; Yialamas MA
    J Clin Endocrinol Metab; 2018 May; 103(5):1715-1744. PubMed ID: 29562364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nebido: a long-acting injectable testosterone for the treatment of male hypogonadism.
    Harle L; Basaria S; Dobs AS
    Expert Opin Pharmacother; 2005 Aug; 6(10):1751-9. PubMed ID: 16086661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endocrine Society of Australia position statement on male hypogonadism (part 2): treatment and therapeutic considerations.
    Yeap BB; Grossmann M; McLachlan RI; Handelsman DJ; Wittert GA; Conway AJ; Stuckey BG; Lording DW; Allan CA; Zajac JD; Burger HG
    Med J Aust; 2016 Sep; 205(5):228-31. PubMed ID: 27581270
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective investigation of testosterone undecanoate depot for the long-term treatment of male hypogonadism in clinical practice.
    Conaglen HM; Paul RG; Yarndley T; Kamp J; Elston MS; Conaglen JV
    J Sex Med; 2014 Feb; 11(2):574-82. PubMed ID: 24279472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current topics in testosterone replacement of hypogonadal men.
    Nieschlag E
    Best Pract Res Clin Endocrinol Metab; 2015 Jan; 29(1):77-90. PubMed ID: 25617174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The current status of therapy for symptomatic late-onset hypogonadism with transdermal testosterone gel.
    Ebert T; Jockenhövel F; Morales A; Shabsigh R
    Eur Urol; 2005 Feb; 47(2):137-46. PubMed ID: 15661407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Opioid-induced hypogonadism: why and how to treat it.
    De Maddalena C; Bellini M; Berra M; Meriggiola MC; Aloisi AM
    Pain Physician; 2012 Jul; 15(3 Suppl):ES111-8. PubMed ID: 22786450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.